Canada · Delayed Price · Currency is CAD Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of CAD 372.21 billion. The enterprise value is 429.67 billion.
| Market Cap | 372.21B |
| Enterprise Value | 429.67B |
Important Dates
The next confirmed earnings date is Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Mar 11, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -3.34% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 37.67% |
| Float | 1.86B |
Valuation Ratios
The trailing PE ratio is 20.55 and the forward PE ratio is 15.03.
| PE Ratio | 20.55 |
| Forward PE | 15.03 |
| PS Ratio | 4.62 |
| PB Ratio | 6.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.64 |
| P/OCF Ratio | 14.25 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.37, with an EV/FCF ratio of 18.05.
| EV / Earnings | 23.72 |
| EV / Sales | 5.51 |
| EV / EBITDA | 13.37 |
| EV / EBIT | 16.84 |
| EV / FCF | 18.05 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 1.17.
| Current Ratio | 0.86 |
| Quick Ratio | 0.55 |
| Debt / Equity | 1.17 |
| Debt / EBITDA | 2.10 |
| Debt / FCF | 2.92 |
| Interest Coverage | 13.36 |
Financial Efficiency
Return on equity (ROE) is 30.35% and return on invested capital (ROIC) is 18.78%.
| Return on Equity (ROE) | 30.35% |
| Return on Assets (ROA) | 10.25% |
| Return on Invested Capital (ROIC) | 18.78% |
| Return on Capital Employed (ROCE) | 20.57% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.07M |
| Profits Per Employee | 240,693 |
| Employee Count | 75,267 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Novartis AG has paid 3.94 billion in taxes.
| Income Tax | 3.94B |
| Effective Tax Rate | 17.88% |
Stock Price Statistics
The stock price has increased by +21.37% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +21.37% |
| 50-Day Moving Average | 29.41 |
| 200-Day Moving Average | 27.14 |
| Relative Strength Index (RSI) | 39.52 |
| Average Volume (20 Days) | 2,506 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of CAD 80.51 billion and earned 18.12 billion in profits. Earnings per share was 9.39.
| Revenue | 80.51B |
| Gross Profit | 60.36B |
| Operating Income | 26.37B |
| Pretax Income | 22.04B |
| Net Income | 18.12B |
| EBITDA | 32.80B |
| EBIT | 26.37B |
| Earnings Per Share (EPS) | 9.39 |
Balance Sheet
The company has 10.82 billion in cash and 69.60 billion in debt, with a net cash position of -58.79 billion.
| Cash & Cash Equivalents | 10.82B |
| Total Debt | 69.60B |
| Net Cash | -58.79B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 59.57B |
| Book Value Per Share | 31.04 |
| Working Capital | -6.24B |
Cash Flow
In the last 12 months, operating cash flow was 26.12 billion and capital expenditures -2.31 billion, giving a free cash flow of 23.81 billion.
| Operating Cash Flow | 26.12B |
| Capital Expenditures | -2.31B |
| Depreciation & Amortization | 6.34B |
| Net Borrowing | 23.02B |
| Free Cash Flow | 23.81B |
| FCF Per Share | n/a |
Margins
Gross margin is 74.98%, with operating and profit margins of 32.75% and 22.50%.
| Gross Margin | 74.98% |
| Operating Margin | 32.75% |
| Pretax Margin | 27.38% |
| Profit Margin | 22.50% |
| EBITDA Margin | 40.74% |
| EBIT Margin | 32.75% |
| FCF Margin | 30.00% |
Dividends & Yields
This stock pays an annual dividend of 0.87, which amounts to a dividend yield of 3.17%.
| Dividend Per Share | 0.87 |
| Dividend Yield | 3.17% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 71.08% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 3.34% |
| Shareholder Yield | 6.50% |
| Earnings Yield | 4.87% |
| FCF Yield | 6.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novartis AG has an Altman Z-Score of 3.36 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.36 |
| Piotroski F-Score | 5 |